The media (Time, Daily Mail) are touting a new study published in the Proceedings of the National Academy of Sciences that links cannabis use to anxiety and depression. The researchers studied the brains of 24 marijuana “abusers” — defined as those who smoke multiple times a day and how they reacted to methylphenidate (more commonly known as Ritalin), a stimulant used to treat ADHD and narcolepsy. Using personality tests and brain imaging, the researchers found the cannabis users had “blunted” (no pun intended, we hope) behavioral, cardiovascular and brain responses to methylphenidate compared with control participants. The “abusers” also scored higher on negative emotional reactions. The researchers conclude that cannabis interferes with the brain’s reaction to dopamine, the chemical responsible for feelings of reward and pleasure.
Lead researcher Nora Volkow of the National Institute on Drug Abuse (NIDA) used methylphenidate because (like cocaine) it raises levels of dopamine in the brain. This was administered to the 48 people in the study — half of whom were cannabis “abusers,” and the other half a control group.
Mitch Earleywine, professor of psychology at SUNY Albany, reached for comment by this reporter, had this to say about the study: “I think that giving folks Ritalin or any other stimulant in an effort to assess dopamine release says little if anything about how cannabis users would respond to natural sources of reinforcement. These people also weren’t randomly assigned to use cannabis, so we have no idea if the altered dopamine reaction preceded or followed cannabis use. Finally, I think if any Big Pharma product did the exact same thing in the lab, we’d be reading about how it protected people against the addictive potential (and induced dopamine release) associated with Ritalin or other stimulants.”
Prof. Earleywine has offered similar reactions to the media’s credulous coverage of much-hyped studies purporting to show a cannabis link to “mental illness.” It should also be noted that High Times just reported on findings published in the journal Psychology & Behavior suggesting that beta-caryophyllene, a terpene found in cannabis, may be effective for treating anxiety and depression. Yet these findings were only touted in such places as High Times and the cannabis-friendly Leaf Science.
Police in Massachusetts Make Super Troopers Reference After Recovering Two Pounds of Weed
Tilray Stock Jumps After News of Exporting CBD to Australia for Epileptic Children
How Many States Allow Medical Marijuana?
Navigating Canada’s Underground Edibles Scene With EP Infusions
Malaysian Court Sentences Man to Death for Distributing Free Cannabis Oil
Canadian Dispensary Clerk Fights off Three Burglars With a Giant Bong
Hot Pot Products: 4 Must-Haves for Cannabis Cultivators
Study Suggests CBD May Have Antipsychotic Effect in High-Risk Individuals
Guides6 days ago
What Do The Colors of Marijuana Mean?
Celebrities6 days ago
Kristen Bell Opens Up About Weekly Cannabis Use and Exploring Other Drugs
Medical Marijuana7 days ago
Canadian Cannabis Company Tilray to Export Products to United States
News7 days ago
Woman Finds Package of Weed in Food Subscription Box
News5 days ago
First Clinical Trial of MDMA Treatment for Autistic Adults Sees Success
Strains5 days ago
9 Colorful Weed Strains To Brighten Your Day
News6 days ago
New Report Says Concentrates are the Fast Growing Favorite Among Consumers
News5 days ago
Study Finds Magic Mushrooms Could Aid in Smoking Cessation